Blue Cross and Blue Shield of Alabama announced it has reduced the copay on Novolog insulin, Asmanex inhalers, Arnuity Ellipta inhalers, and QVAR RediHalers. The provider said they’re striving to alleviate financial burdens and make the products more readily available at lower prices for members.

According to BCBS of Alabama, the following adjustments took effect on April 1, 2024:

Insulin

In order to ensure low net cost, the manufacturer of Novolog insulin recently reduced its price of insulin products and partnered with Blue Cross through the insurance company’s Pharmacy Benefit Manager (PBM), Prime Therapeutics. Because of the partnership, Blue Cross will pass the savings directly to their members by reducing their co-pays to the lowest possible level for Novolog insulin.

Inhalers

GlaxoSmithKline discontinued production of their Flovent HFA inhaler and also launched an authorized generic. To help keep inhaler costs as low as possible for Blue Cross members, the company in turn reduced the cost shares of alternatives including Asmanex inhalers, Arnuity Ellipta inhalers, and QVAR RediHalers.

Austen Shipley is a staff writer for Yellowhammer News.